Synergistic antioxidant capacity of CsNPs and CurNPs against cytotoxicity, genotoxicity and pro-inflammatory mediators induced by hydroxyapatite nanoparticles in male rats.
Journal
Toxicology research
ISSN: 2045-452X
Titre abrégé: Toxicol Res (Camb)
Pays: England
ID NLM: 101587950
Informations de publication
Date de publication:
01 Nov 2019
01 Nov 2019
Historique:
received:
19
08
2019
accepted:
24
09
2019
entrez:
25
3
2020
pubmed:
25
3
2020
medline:
25
3
2020
Statut:
epublish
Résumé
Due to their dynamic characteristics, hydroxyapatite nanoparticles (HAP-NPs) have been employed numerous times in nanomedicine and in tissue engineering, particularly as diagnostic and therapeutic agents. However, there are outstanding findings from various studies that question whether these NPs are safe when they are used in the human body. Therefore, a more in-depth toxicity assessment should be carried out to give a clear answer regarding the fate of these particles. Here we aim to investigate the possible cytotoxicity, genotoxicity and inflammation induced by HAP-NPs, as well as predict the synergistic antioxidative effect of chitosan nanoparticles (CsNPs) and curcumin nanoparticles (CurNPs) in mitigating this pronounced toxicity. The present study was conducted on eighty Wistar male rats, divided into eight equal groups. The results showed that, at the molecular level, HAP-NPs significantly induced gene expression of tumor suppressor protein p53, tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6) and also Kidney Injury Molecule-1 (KIM-1) and Lipocalin-2 (LCN2). In addition, kidney biochemical parameters (total bilirubin, urea, uric acid and creatinine) increased, but albumin levels decreased in the group treated with HAP-NPs alone. Meanwhile, co-treatment with CsNPs and/or CurNPs with HAP-NPs showed an improvement in the activities of the kidney parameters and reduced inflammation. This study shows that the nephrotoxicity mechanism of HAP-NPs may involve various signaling pathways including alterations in biochemical parameters, gene expression of KIM-1 and LCN2 and disturbing the production of cytokines and p53. Furthermore, these insights showed that the combined effect of both CsNPs and CurNPs was more pronounced than the effect of each one on its own.
Identifiants
pubmed: 32206303
doi: 10.1039/c9tx00221a
pii: c9tx00221a
pmc: PMC7069401
doi:
Types de publication
Journal Article
Langues
eng
Pagination
939-952Informations de copyright
This journal is © The Royal Society of Chemistry 2019.
Références
Bioorg Med Chem. 2011 Jan 1;19(1):21-9
pubmed: 21115252
Life Sci. 2006 Mar 27;78(18):2081-7
pubmed: 16413584
Chem Biol Interact. 2012 Jul 30;199(1):49-61
pubmed: 22704994
Curr Mol Med. 2006 Sep;6(6):651-63
pubmed: 17022735
Inflammopharmacology. 2017 Dec;25(6):609-619
pubmed: 28921388
Nat Immunol. 2001 Feb;2(2):95-101
pubmed: 11175800
Biomaterials. 2004 Aug;25(19):4749-57
pubmed: 15120521
Eur J Pharm Sci. 2005 Jul-Aug;25(4-5):427-37
pubmed: 15893461
Environ Health Perspect. 2005 Jul;113(7):823-39
pubmed: 16002369
Onco Targets Ther. 2015 Jan 29;8:295-302
pubmed: 25674004
Oral Oncol. 2009 Mar;45(3):266-72
pubmed: 18715816
J Clin Invest. 2005 Mar;115(3):610-21
pubmed: 15711640
Am J Clin Exp Immunol. 2014 Feb 27;3(1):30-6
pubmed: 24660119
Immunogenetics. 2017 Jun;69(6):371-378
pubmed: 28478481
Am J Physiol Renal Physiol. 2006 Feb;290(2):F517-29
pubmed: 16174863
Clin Exp Pharmacol Physiol. 2012 Mar;39(3):283-99
pubmed: 22118895
Occup Environ Med. 2004 Sep;61(9):727-8
pubmed: 15317911
Am J Nephrol. 2004 May-Jun;24(3):307-15
pubmed: 15148457
Biomed Mater. 2011 Jun;6(3):035003
pubmed: 21487174
Curr Med Chem. 2011;18(4):539-51
pubmed: 21143112
Appl Biochem Biotechnol. 2007 Jan;136(1):77-96
pubmed: 17416979
Cancer Invest. 2009 Oct;27(8):825-9
pubmed: 19544111
Clin Exp Immunol. 2003 Mar;131(3):528-35
pubmed: 12605707
Breast Cancer Res Treat. 2010 Aug;122(3):777-85
pubmed: 19898931
J Biomater Appl. 2019 Feb;33(7):946-954
pubmed: 30541364
Am J Physiol Renal Physiol. 2004 Mar;286(3):F552-63
pubmed: 14600030
Biomaterials. 2009 Mar;30(8):1502-11
pubmed: 19118895
Cell Mol Life Sci. 2008 Jun;65(11):1631-52
pubmed: 18324353
Toxicol Sci. 2008 Jun;103(2):371-81
pubmed: 18308701
Nephrol Dial Transplant. 2011 Mar;26(3):762-4
pubmed: 21310736
Vaccine. 2000 Nov 8;19(6):661-8
pubmed: 11090719
Adv Chronic Kidney Dis. 2005 Oct;12(4):353-65
pubmed: 16198274
Environ Health Perspect. 2004 Mar;112(4):465-79
pubmed: 15033597
J Immunol. 2008 Aug 15;181(4):2806-12
pubmed: 18684972
J Am Soc Nephrol. 2003 Oct;14(10):2534-43
pubmed: 14514731
Br J Pharmacol. 2007 Oct;152(4):421-8
pubmed: 17641669
Curr Opin Nephrol Hypertens. 2001 May;10(3):321-9
pubmed: 11342793
Biochem Pharmacol. 2010 Feb 1;79(3):330-8
pubmed: 19735646
Apoptosis. 2007 Jan;12(1):113-23
pubmed: 17136495
ScientificWorldJournal. 2014 Feb 11;2014:898361
pubmed: 24678280
J Immunol. 2012 Jun 15;188(12):6287-99
pubmed: 22566565
Nature. 2008 Jul 24;454(7203):436-44
pubmed: 18650914
Biol Pharm Bull. 2007 Jan;30(1):128-32
pubmed: 17202672
Br J Pharmacol. 2017 Jul;174(13):2074-2084
pubmed: 28409821
Biomacromolecules. 2012 Jan 9;13(1):146-53
pubmed: 22168363
J Appl Toxicol. 2017 Aug;37(8):1004-1016
pubmed: 28261831
Toxicol Pathol. 2005;33(3):343-55
pubmed: 15805072
Sci Rep. 2017 Aug 31;7(1):10114
pubmed: 28860665
Toxicology. 2008 Mar 20;245(3):182-93
pubmed: 18294749
Apoptosis. 2009 Jan;14(1):108-23
pubmed: 19082730
Materials (Basel). 2017 Mar 24;10(4):
pubmed: 28772697
Toxicol Rep. 2015 May 12;2:737-747
pubmed: 28962409
Bioorg Med Chem Lett. 2001 Jul 9;11(13):1699-701
pubmed: 11425541
Eur Respir J. 2008 Feb;31(2):241-51
pubmed: 18057054
Acta Biomater. 2009 Jun;5(5):1708-15
pubmed: 19231306
Biomaterials. 2009 Aug;30(23-24):3891-914
pubmed: 19427031
J Am Soc Nephrol. 2007 Feb;18(2):407-13
pubmed: 17229907
J Soc Integr Oncol. 2007 Winter;5(1):25-37
pubmed: 17309811
J Biomed Mater Res A. 2015 Jul;103(7):2499-507
pubmed: 25530348
Clin J Am Soc Nephrol. 2010 Nov;5(11):1954-9
pubmed: 20813857
Mol Pharmacol. 2008 Nov;74(5):1234-45
pubmed: 18676676